Deal Library / Pharma BD Deal Intelligence

Novo Nordisk A/S — Pharma Deals

The Pharma Closeout tracks 13 deals, $29.8B in disclosed deal value, 8 with a post-close Outcome Score for Novo Nordisk A/S.

Median Critic Score: 88 · Median Outcome Score: 68

All 13 deals

Novo Nordisk A/S / Emisphere Technologies — 2020 · $1.4B · Worked — the deal delivered on its rationale.
Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. — 2019 · $3.3B · Worked — the deal delivered on its rationale.
Novo Nordisk A/S / Vivtex Inc. — 2026 · $2.1B · Largely worked — most objectives met.
Novo Nordisk A/S / Forma Therapeutics Holdings Inc. — 2022 · $1.1B · Largely worked — most objectives met.
Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. — 2021 · $3.3B · Largely worked — most objectives met.
Novo Nordisk A/S / Inversago Pharma — 2023 · $1.1B · Largely worked — most objectives met.
Novo Nordisk A/S / Forma Therapeutics Holdings Inc. — 2022 · $1.1B · Mixed — partial payoff, real shortfalls.
Novo Nordisk A/S / KBP Biosciences — 2023 · $1.3B · Did not work — the deal failed to deliver.
Novo Nordisk A/S / Akero Therapeutics, Inc. — 2025 · $5.2B
Novo Nordisk A/S / Lexicon Pharmaceuticals Inc. — 2025 · $1.0B
Novo Nordisk A/S / Neomorph Inc. — 2024 · $1.5B
Novo Nordisk A/S / Aspect Biosystems Ltd. — 2023 · $2.7B
Novo Nordisk A/S / Valo Health, Inc. — 2023 · $4.8B